Lexicon Pharmaceuticals Inc. is seeking to close the books on the 10-year development program for sotagliflozin (previously LX-4211), its oral dual inhibitor of sodium glucose co-transporter (SGLT) 1 and 2, in type 1 diabetes (T1D). The company's pivotal phase III trial showed that individuals with T1D treated with sotagliflozin achieved statistically significant reductions in A1C at 24 weeks. Less favorable was a small incidence of diabetic ketoacidosis (DKA) in the treatment arms, an issue that has dogged SGLT2 inhibitors as a class.